Let's learn together about many interesting topics.
Should we start with an existing legacy space or a green space? Why is Good Manufacturing Practices (GMP) crucial for your radioisotope production?
Dr Richard Freifelder from University of Chicago recently shared his experience on how to set up a radiopharmacy by focusing on the challenges and opportunities through 2 case studies: a legacy space or a green field.
Watch the webinar with Dr Freifelder
Our IBA experts guide you through the important steps to set-up your GMP radiopharmacy.
How does a cyclotron accelerate particles using electric and magnetic fields? Which role do cyclotrons play in producing radioisotopes?
A bit nostalgic today, Mr Ion would like to share the video of his birth with you.
Follow Mr Ion during his birth and learn all about the cyclotrons' process in only 1 minute!
How is a cyclotron built?
Thanks to Mr Ion, now you know how a cyclotron accelerates particles. But do you know how a cyclotron is designed, built, tested and validated?
Basically, radiochemistry is the chemistry of radioactive materials. It is quite broad so let's be more specific.
Radiochemists have the option to perform their syntheses manually or using semi-automatic or fully automatic synthesizers to develop and optimize the production of radiopharmaceuticals. The use of synthesizers results in a more robust and stable process that aligns with Good Manufacturing Practices (GMP). Additionally, the remote automated operation of these synthesizers reduces radiation exposure of the radiochemists.
By developing new radiolabeling techniques to incorporate radioisotopes into specific molecules, radiochemists create innovative radiopharmaceuticals used to improve disease diagnosis and therapy.
Are you curious to learn more about new radiochemistry developments and clinical routine applications?
Did you know that radioisotopes have been a game changer in medical diagnosis and treatment?
First, let's go back to the end of the 19th century when Henri Becquerel, a French engineer and physicist, observed radiation on uranium. This was followed by intensive research with Pierre and Marie Curie who pioneered the science of radioactivity by discovering radioactive elements like polonium and radium.
Marie Curie's research significantly contributed to the development of critical radioisotopes that reshaped medical diagnostics and treatments. Like radioisotope 131I (Iodine-131), discovered in 1938 by Glenn Seaborg and John Livingood, that is still widely used for the diagnosis and treatment of thyroid diseases.
Over the decades, radioisotopes' production has constantly evolved, from manual to automated processes with cyclotrons, nuclear accelerators and generators allowing the creation of more than 3000 radioisotopes for various medical applications.
The future of radioisotopes is still promising with the new era of radiotheranostics. Stay tuned for our next episode hereabout!
Radiotheranostic is the unique customized medical approach combining diagnostic and therapeutic radionuclides to diagnose, treat and monitor cancer tumors.
Developing, producing and distributing radiotheranostics is a major challenge for several reasons. One of them is the half-life of the radioisotopes. The time that it takes for half the radionuclides to disintegrate or decay is called half-life. The longer the half-life, the easier it is to envision centralized distribution.
Radiotheranostics can be used in several medical applications, such as neuroendocrine tumors, prostate cancer, non-Hodgkin's lymphoma, thyroid diseases, brain tumors, and much more. Research in this area is highly active and promising.
As IBA RadioPharma Solutions, we are focusing on unlocking alpha emitters for theranostic applications by addressing critical market availability challenges of radiopharmaceuticals and radionuclides such as astatine-211 and actinium-225.
Based on the World Health Organization, Alzheimer's and neurodegenerative diseases are the 7th leading cause of mortality worldwide.
To improve early diagnosis and appropriate treatment, many clinical trials are being conducted on these pathologies worldwide. Recently, two additional disease-modifying-therapies for Alzheimer's have been approved by the US FDA: Lequemi® from Eisai and last month Kinsula® from Eli Lilly.
The clinical expression of the Alzheimer's Disease (AD) is preceded by the pathological accumulation of amyloid-beta (Aβ) plaques and hyperphosphorylated tau proteins as well as neuronal damage and synaptic failure. One of the most significant advances in diagnostics is the use of Positron Emission Tomography (PET) imaging to visualize amyloid-beta (Aβ) plaques and tau protein deposition.
PET imaging, along with other AD biomarkers, has been instrumental in redefining the criteria for clinical trials helping advancing AD therapies. It is used to determine a patient’s eligibility for the new treatments.
Will the approval of novel AD drugs unleash the use of Amyloid PET imaging?